دورية أكاديمية
أعرض في EDS

High-Throughput Sequencing of BACHD Mice Reveals Upregulation of Neuroprotective miRNAs at the Pre-Symptomatic Stage of Huntington's Disease.

التفاصيل البيبلوغرافية
العنوان: High-Throughput Sequencing of BACHD Mice Reveals Upregulation of Neuroprotective miRNAs at the Pre-Symptomatic Stage of Huntington's Disease.
المؤلفون: Olmo IG; Department of Biochemistry and Immunology, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, Belo Horizonte, Brazil., Olmo RP; Department of Biochemistry and Immunology, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, Belo Horizonte, Brazil.; CNRS UPR9022, Inserm U1257, Institut de Biologie Moléculaire et Cellulaire, Université de Strasbourg, Strasbourg, France., Gonçalves ANA; Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, Universidade de São Paulo, São Paulo, Brazil., Pires RGW; Department of Physiological Sciences, Center for Health Sciences, Universidade Federal do Espirito Santo, Vitoria, Brazil., Marques JT; Department of Biochemistry and Immunology, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, Belo Horizonte, Brazil.; CNRS UPR9022, Inserm U1257, Institut de Biologie Moléculaire et Cellulaire, Université de Strasbourg, Strasbourg, France., Ribeiro FM; Department of Biochemistry and Immunology, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, Belo Horizonte, Brazil.
المصدر: ASN neuro [ASN Neuro] 2021 Jan-Dec; Vol. 13, pp. 17590914211009857.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Sage Country of Publication: United States NLM ID: 101507115 Publication Model: Print Cited Medium: Internet ISSN: 1759-0914 (Electronic) Linking ISSN: 17590914 NLM ISO Abbreviation: ASN Neuro Subsets: MEDLINE
أسماء مطبوعة: Publication: <2014-> : Thousand Oaks, CA : Sage
Original Publication: [London] : Portland Press, 2009-
مواضيع طبية MeSH: Prodromal Symptoms*, High-Throughput Nucleotide Sequencing/*methods , Huntington Disease/*genetics , MicroRNAs/*biosynthesis , MicroRNAs/*genetics , Neuroprotection/*physiology, Animals ; Cells, Cultured ; Female ; Huntington Disease/metabolism ; Huntington Disease/prevention & control ; Male ; Mice ; Mice, Inbred C57BL ; Mice, Transgenic ; Sequence Analysis, RNA/methods ; Up-Regulation/physiology
مستخلص: Huntington's disease (HD) is a genetic disorder marked by transcriptional alterations that result in neuronal impairment and death. MicroRNAs (miRNAs) are non-coding RNAs involved in post-transcriptional regulation and fine-tuning of gene expression. Several studies identified altered miRNA expression in HD and other neurodegenerative diseases, however their roles in early stages of HD remain elusive. Here, we deep-sequenced miRNAs from the striatum of the HD mouse model, BACHD, at the age of 2 and 8 months, representing the pre-symptomatic and symptomatic stages of the disease. Our results show that 44 and 26 miRNAs were differentially expressed in 2- and 8-month-old BACHD mice, respectively, as compared to wild-type controls. Over-representation analysis suggested that miRNAs up-regulated in 2-month-old mice control the expression of genes crucial for PI3K-Akt and mTOR cell signaling pathways. Conversely, miRNAs regulating genes involved in neuronal disorders were down-regulated in 2-month-old BACHD mice. Interestingly, primary striatal neurons treated with anti-miRs targeting two up-regulated miRNAs, miR-449c-5p and miR-146b-5p, showed higher levels of cell death. Therefore, our results suggest that the miRNAs altered in 2-month-old BACHD mice regulate genes involved in the promotion of cell survival. Notably, over-representation suggested that targets of differentially expressed miRNAs at the age of 8 months were not significantly enriched for the same pathways. Together, our data shed light on the role of miRNAs in the initial stages of HD, suggesting a neuroprotective role as an attempt to maintain or reestablish cellular homeostasis.
References: Exp Cell Res. 2014 Feb 1;321(1):84-9. (PMID: 24099990)
Trends Genet. 2004 Mar;20(3):146-54. (PMID: 15036808)
Cancer. 2010 Jan 1;116(1):41-9. (PMID: 19890957)
Trends Cell Biol. 2013 Jan;23(1):30-6. (PMID: 23026030)
Bioinformatics. 2018 Jul 1;34(13):2322-2324. (PMID: 29949954)
Anticancer Drugs. 2017 Nov;28(10):1067-1078. (PMID: 29023247)
Front Immunol. 2017 Aug 23;8:1016. (PMID: 28878777)
PLoS One. 2016 Sep 15;11(9):e0162788. (PMID: 27631085)
Hum Mol Genet. 2003 May 1;12(9):985-94. (PMID: 12700167)
Int J Mol Med. 2020 Apr;45(4):1091-1102. (PMID: 32124967)
J Neurosci. 2008 Dec 31;28(53):14341-6. (PMID: 19118166)
Acta Neuropathol. 2008 Jan;115(1):55-69. (PMID: 17978822)
Neurobiol Dis. 2008 Mar;29(3):438-45. (PMID: 18082412)
Nat Struct Mol Biol. 2009 Jan;16(1):23-9. (PMID: 19079265)
Genome Biol. 2009;10(3):R25. (PMID: 19261174)
Genome Biol. 2014;15(12):550. (PMID: 25516281)
Neurosci Lett. 1991 Dec 9;133(2):257-61. (PMID: 1840078)
J Neuroimmunol. 2016 Apr 15;293:71-81. (PMID: 27049565)
Am J Hum Genet. 2013 Aug 8;93(2):306-12. (PMID: 23810380)
Nat Genet. 2011 Mar 20;43(4):371-8. (PMID: 21423181)
Br J Pharmacol. 2013 Jun;169(4):909-21. (PMID: 23489026)
Oncogene. 2018 Jun;37(25):3369-3383. (PMID: 29353884)
PLoS One. 2013;8(1):e54222. (PMID: 23349832)
Yonsei Med J. 2020 Aug;61(8):660-669. (PMID: 32734729)
PLoS One. 2011;6(8):e23837. (PMID: 21887328)
EMBO J. 2016 Nov 15;35(22):2386-2398. (PMID: 27707753)
Cell. 2007 Dec 14;131(6):1097-108. (PMID: 18083100)
Pharmacol Ther. 2012 Feb;133(2):142-50. (PMID: 22008259)
Mol Cancer. 2017 Jan 19;16(1):15. (PMID: 28103887)
Mol Cell Neurosci. 2009 Feb;40(2):121-7. (PMID: 18992820)
Dev Cell. 2002 Jun;2(6):831-7. (PMID: 12062094)
Brain. 2014 Mar;137(Pt 3):819-33. (PMID: 24459107)
Nat Genet. 2004 Jun;36(6):585-95. (PMID: 15146184)
Mol Cancer. 2011 Mar 18;10:29. (PMID: 21418558)
Sci Rep. 2016 Dec 06;6:38339. (PMID: 27922090)
Mediators Inflamm. 2016;2016:8653132. (PMID: 27578922)
Neuron. 2005 Jul 7;47(1):29-41. (PMID: 15996546)
Transl Neurodegener. 2014 Aug 18;3:17. (PMID: 25210621)
Exp Neurol. 2011 Jan;227(1):172-9. (PMID: 21035445)
J Neuropathol Exp Neurol. 1985 Nov;44(6):559-77. (PMID: 2932539)
J Neurosci. 2008 Jun 11;28(24):6182-95. (PMID: 18550760)
BMC Med Genomics. 2015 Mar 01;8:10. (PMID: 25889241)
Nat Rev Neurosci. 2013 Oct;14(10):708-21. (PMID: 24052178)
Dig Dis Sci. 2014 Feb;59(2):336-45. (PMID: 24248414)
Front Mol Neurosci. 2019 Jun 19;12:156. (PMID: 31275113)
Noncoding RNA Res. 2018 Jul 31;3(3):154-159. (PMID: 30175288)
Cell. 1993 Mar 26;72(6):971-83. (PMID: 8458085)
Trends Genet. 2003 May;19(5):233-8. (PMID: 12711212)
Neurology. 2018 Jan 23;90(4):e264-e272. (PMID: 29282329)
Nucleic Acids Res. 2020 Jul 2;48(W1):W521-W528. (PMID: 32374865)
Nature. 2014 Jun 5;510(7503):115-20. (PMID: 24899310)
Nucleic Acids Res. 2010 Nov;38(20):7219-35. (PMID: 20591823)
Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):E2851-7. (PMID: 24982181)
J Neuroinflammation. 2019 Nov 14;16(1):220. (PMID: 31727077)
Genes Dev. 1999 Nov 15;13(22):2905-27. (PMID: 10579998)
PLoS One. 2018 Jan 11;13(1):e0190550. (PMID: 29324753)
Front Cell Neurosci. 2013 Dec 19;7:265. (PMID: 24391543)
PLoS Genet. 2014 Feb 27;10(2):e1004188. (PMID: 24586208)
Exp Cell Res. 1999 Nov 25;253(1):210-29. (PMID: 10579924)
Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3498-503. (PMID: 14993615)
فهرسة مساهمة: Keywords: BACHD; Huntington’s disease; miR-146b-5p; miR-449c-5p; microRNA; pre-symptomatic stage
المشرفين على المادة: 0 (MIRN149 microRNA, mouse)
0 (MicroRNAs)
0 (Mirn146 microRNA, mouse)
تواريخ الأحداث: Date Created: 20210428 Date Completed: 20211130 Latest Revision: 20220101
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC8718118
DOI: 10.1177/17590914211009857
PMID: 33906482
قاعدة البيانات: MEDLINE
الوصف
تدمد:1759-0914
DOI:10.1177/17590914211009857